Phase 1 (M14-546): Mivebresib (ABBV-075) in Patients With Advanced Cancer

**Key Inclusion Criteria**

- Dose escalation cohorts: Advanced or metastatic solid tumor that is either refractory after standard of care therapy or for which standard of care therapy does not exist
- Expansion cohorts: AML and prostate cancer that is either refractory after standard of care therapy or standard of care therapy does not exist
- ECOG PS 0-1 (dose escalation cohorts) or 0-2 (expansion cohorts)
- Adequate bone marrow, hepatic and renal function

**Key Exclusion Criteria**

- Untreated brain or meningeal metastases
- Uncontrolled hypertension
- History of long QT syndrome

**Endpoints**

**Primary:** MTD, AE, Cmax, Tmax, AUC  
**Secondary:** ORR, PFS, DOR

ABBV-075 is an investigational drug that is not approved by the FDA. Safety and efficacy have not been established.

Venetoclax is being investigated for indications that have not been approved by Regulatory Agencies. Safety and Efficacy have not been established in unapproved indications.

To learn more about these studies, please visit [https://ClinicalTrials.gov](https://ClinicalTrials.gov) or email abbvieclinicaltrials@abbvie.com

Venetoclax is being codeveloped by AbbVie and Genentech, a member of the Roche Group.